Liver Cancer Drugs Market, By By Therapeutic Class (Immunotherapy, Targeted Therapy), By Type (Hepatocellular Carcinoma, Hepatoblastoma, Cholangio Carcinoma), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast From 2020 – 2026

Report ID: AMI-19081972 | Publihed: 01-Jul-2020 | No of Pages: 165


USD 3995
USD 5795


Publish Date:


Total pages:


Liver cancer drugs market was valued at USD 630.1 million by 2019, growing with 16.4% CAGR during the forecast period, 2020-2026
Market Dynamics
Liver cancer is estimated to be the fifth most prevalent cancer and accounts for about 9.0% of all cancer deaths across the globe. In 2012, around 782,451 novel cases of liver cancer were diagnosed, of which 745,533 deaths were reported due to the life-threatening disease. Primary liver cancer remains a significant public health issue owing to poor survival rate and its extremely aggressive nature. Hepatocellular carcinoma is one of the most common types of liver cancer that begins in the hepatocyte, which is the main type of liver cell.
The growing prevalence of liver cancer, government initiatives to increase cancer awareness, and increasing investments in R&D activities to develop novel therapies are the major factors driving the growth of global liver cancer drugs market. In addition, the large amount of the population is exposed to certain risk factors contributing to liver cancer owing to the growing adoption of unhealthy lifestyle by people. Also, heavy consumption of alcohol and tobacco smoking are the encouraging factors for liver cancer. Thus, the above-mentioned factors will propel the market growth during the forecast period. The estimations by the American Cancer Society states that there would be around 42,810 novel cases of liver cancer in the U.S. by the end of 2020. Moreover, the rising demand for therapeutic drugs for the treatment of liver cancer is likely to create lucrative opportunities in the global industry. However, a dearth in the number of donors and the diagnosis of disease in the advanced stage with no feasibility of transplantation or surgery is predicted to restrict the market growth in the coming future.
Therapeutic Class Takeaway
The immunotherapy segment is anticipated to generate the majority of share in the global market owing to increasing R&D investments and the launch of novel drugs for treating liver cancer. If patients have an adequate reserve for hepatic function, the optimal treatment for HCC is a partial surgical resection. The resection of cirrhotic livers can grow the risk of liver failure which is a fatal complication. However, the resection rates have improved hugely after resection over the past few decades. On the other hand, the relapse rates are very high for after surgical resection. In the treatment of HCC, most of the systemic drugs have minimal efficacy, and thus R&D is primarily focused on hepatocarcinogenesis.
The HCC or hepatocellular carcinoma is the most common form of liver cancer. HCC mostly occurs in people who are suffering from chronic liver diseases such as cirrhosis. It is also one of the major causes of cancer-related deaths all across the globe. It is observed that the African and Asian countries have higher prevalence rates of hepatocellular carcinoma as compared to the developed economies. This is majorly owing to the disparity in the main risk factors causing HCC such as hepatitis B and C virus infection in these regions. With the rise in the occurrence of hepatocellular carcinoma, there is projected to be a huge demand for liver cancer drugs. Hence, the growing prevalence of cancer and the rise in unmet medical needs are the significant factors driving the segmental market growth of HCC during the period of forecast.
Regional Takeaway
Presently, the North America region is dominating the market owing to the growing geriatric population and the presence of well-established healthcare infrastructure in this region. On the other hand, the Asia Pacific market for liver cancer drugs will grow at a notable rate owing to the higher prevalence rates of HCC than other regions in the world.
Key vendors of the market include:
• Merck
• Bristol-Myers Squibb
• Bayer
• Eisai
• Exelixis
• Ono Pharmaceutical
• Onyx Pharmaceuticals Inc
• Alnylam Pharmaceuticals, Inc
• Pfizer Inc
• F. Hoffmann-La Roche Ltd.
The market size and forecast for each segment and sub-segments has been considered as below:
• Historical Year – 2015 to 2018
• Base Year – 2019
• Estimated Year – 2020
• Projected Year – 2026
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
The scope of this report covers the market by its major segments, which include as follows:
? Immunotherapy
? Targeted Therapy
? Hepatoblastoma
? Hepatocellular Carcinoma
? Cholangio Carcinoma
? Others
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.